Peptide Perspectives™

BEYOND WEIGHT LOSS

Peptides, Metabolic Health & Insulin Resistance

METABOLIC HEALTH IS MORE THAN WEIGHT

- Glucose control
- Insulin sensitivity
- Liver and heart health
- Cellular energy

Weight and metabolic health are related, but not interchangeable.

HOW THE SYSTEM WORKS



Insulin resistance means muscle, liver and fat respond less effectively to insulin.

EIGHT COMPOUNDS UNDER STUDY

ESTABLISHED HUMAN EVIDENCE

Semaglutide
GLP-1
FDA-approved for defined indications

Tirzepatide
GIP + GLP-1
FDA-approved for defined indications

CLINICAL RESEARCH OR GEOGRAPHICALLY APPROVED

Mazdutide
GLP-1 + glucagon
Approved in China, not FDA-approved

Retatrutide
GIP + GLP-1 + glucagon
Phase 3; investigational

EARLY EXPERIMENTAL RESEARCH

MOTS-c	Mitochondrial signaling	Preclinical efficacy; human benefit unproven
5-Amino-1MQ	NNMT inhibition	Preclinical; NOT a peptide
AICAR	AMPK research tool	Small human physiology studies; NOT a peptide
Pancragen	Pancreatic-cell signaling	Preliminary evidence only

HUMAN CLINICAL SIGNALS

Mazdutide
HbA1c down ~1.57 to 2.15 percentage points
DREAMS-1, 24 weeks

Retatrutide
HbA1c down ~1.69 to 1.94 percentage points
Phase 3, 40 weeks

Tirzepatide
Improved HbA1c and model-derived insulin-resistance markers
SURPASS-2

Values are from distinct studies, not directly comparable.

WHAT RESEARCHERS MEASURE

- HbA1c & fasting glucose
- Insulin response
- Liver fat & lipids
- Blood pressure & function

THE NEXT FRONTIER

- Metabolic flexibility
- Pancreatic resilience
- Long-term organ protection

Clinical evidence varies. Weight-loss-related and direct metabolic effects must be distinguished. Experimental compounds are not validated diabetes treatments.

Educational overview • Peptide Perspectives • November 2026